Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Tovecimig (CTX-009) Meets Primary Endpoint in Ph 2/3 Study in Patients with Biliary Tract Cancer

April 8, 2025

Preliminary positive immune response data announced from Ph 3 clinical trial FLAMINGO-01 of GLSI-100

April 8, 2025

SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer

April 8, 2025

SC Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior PK Compared to IV KEYTRUDA in Pivotal 3475A-D77 Trial

April 2, 2025

FAILED TRIAL: Ph 3 ARTISTRY-7 Trial of Nemvaleukin + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer did not achieve a statistically significant improvement in OS

April 2, 2025

Primary Endpoint Met in Pivotal Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

April 2, 2025

RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) outperform osimertinib with a significant OS benefit in patients with EGFR-mutated NSCLC

April 2, 2025

Results Announced from Ph 2a Trial of VXM01 and Avelumab Combination Therapy in GBM

April 2, 2025

In LAURA Ph 3 trial, Tagrisso continues to demonstrate improved OS trend in unresectable, Stage III setting

April 2, 2025

75.5% CR at any time in Ph 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS)

April 2, 2025

Positive Preliminary Ph 1b/2 Data of Olvi-Vec in Advanced SCLC Announced

April 2, 2025

Positive Updated Data Reported from Sirexatamab CRC Study

April 2, 2025

Both Prolonged Median OS and Long Tail of Survival in Ph 2a Trial of CAN-2409 in Advanced NSCLC Patients Non-Responsive to ICI Treatment Reported 

April 2, 2025

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

March 26, 2025

FRUSICA-2 Ph 2/3 Study of Sintilimab and Fruquintinib Combination Met Primary Endpoint in Advanced RCC in China

March 26, 2025

SGO 2025: Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer

March 26, 2025

Positive Topline Results from Ph 3 VERITAC-2 Clinical Trial Announced

March 18, 2025

Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 (Tedopi) in Advanced Pancreatic Cancer Announced

March 18, 2025

SGO 2025: ELAHERE (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

March 18, 2025

Actimab-A + CLAG-M Trial Results in Patients with R/R AML published in the Journal Leukemia

March 18, 2025

Updated 18-Month DOR of 80.6% from Ph 3 ENVISION Trial of UGN-102 Announced

March 18, 2025

JAMA Study suggests that Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

March 18, 2025

SGO 2025: Updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC announced

March 18, 2025

SGO 2025: Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer Presented

March 18, 2025

SGO 2025: Rinatabart Sesutecan (Rina-S) Shows Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

March 18, 2025
Page1 Page2 Page3 Page4 Page5 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.